Nimbus Therapeutics

- Highly selective SIK2 inhibitors demonstrate dual mechanism of suppressing inflammation while promoting pro-resolution and tissue repair pathways - BOSTON, Mass. - April 16, 2026 - Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug dis

- Highly selective SIK2 inhibitors demonstrate dual mechanism of suppressing inflammation and promoting mucosal healing in preclinical models and human ex vivo systems - BOSTON-(BUSINESS WIRE)-Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"),

- New collaboration follows previous Lilly and Nimbus AMPK research collaboration in cardiometabolic disease - BOSTON, Mass. - January 6, 2026 - Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough

BOSTON, Mass. - December 19, 2025 - Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the comple

- First participants dosed in Phase 1/2 clinical trial - - Preclinical data supporting best-in-class potential of NDI-219216 to be presented at AACR Annual Meeting 2025 - BOSTON, Mass. - April 25, 2025 - Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or

BOSTON, Mass. - March 7, 2025 - Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced t

BOSTON, Mass. - February 25, 2025 - Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announc

- Completion of IND submission for NDI-219216, a non-covalent WRN inhibitor for treatment of MSI-H tumors, with plans to initiate clinical trial in 1H 2025 - - Appointment of Peter J. Tummino as President of R&D - - Company to present pipeline update at 4

- NDI-101150 monotherapy achieved 18% objective response rate in heavily pretreated renal cell carcinoma (RCC) patients with prior exposure to checkpoint inhibitors - - Clinical benefit rate of 29% and disease control rate of 65% observed in RCC patients

New development candidate, NTX-452, a non-covalent WRN inhibitor, demonstrated significant tumor regression and complete responses at low oral doses in MSI-H tumor models refractory to immunotherapy and chemotherapy Company plans to initiate clinical tria